Free Trial
NASDAQ:TECX

Tectonic Therapeutic Q3 2025 Earnings Report

Tectonic Therapeutic logo
$28.56 -0.54 (-1.86%)
Closing price 06/9/2026 04:00 PM Eastern
Extended Trading
$26.68 -1.88 (-6.60%)
As of 06/9/2026 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tectonic Therapeutic EPS Results

Actual EPS
-$1.02
Consensus EPS
-$1.05
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Tectonic Therapeutic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tectonic Therapeutic Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Tectonic Therapeutic's Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Tectonic Therapeutic Earnings Headlines

Tectonic Therapeutic Inc TECX
One page of the SpaceX S-1 will move this stock overnight
When SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including power consumption for 1 million GPUs, a cost that rivals entire cities. That disclosure will name the supplier. One small, publicly traded power infrastructure company sits at the center of this - carrying a $1.5 billion backlog and priced like a utility. Dylan Jovine has the full breakdown.tc pixel
See More Tectonic Therapeutic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tectonic Therapeutic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tectonic Therapeutic and other key companies, straight to your email.

About Tectonic Therapeutic

Tectonic Therapeutic (NASDAQ:TECX) engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

View Tectonic Therapeutic Profile